Axogen (LT3) Stock Overview
Engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
LT3 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Axogen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.40 |
| 52 Week High | US$30.60 |
| 52 Week Low | US$7.85 |
| Beta | 1.02 |
| 1 Month Change | -15.86% |
| 3 Month Change | -10.95% |
| 1 Year Change | 45.24% |
| 3 Year Change | 221.05% |
| 5 Year Change | 36.31% |
| Change since IPO | 216.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| LT3 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -4.7% | -4.0% | -5.4% |
| 1Y | 45.2% | -25.0% | -2.4% |
Return vs Industry: LT3 exceeded the German Medical Equipment industry which returned -23.8% over the past year.
Return vs Market: LT3 exceeded the German Market which returned 0.7% over the past year.
Price Volatility
| LT3 volatility | |
|---|---|
| LT3 Average Weekly Movement | 8.6% |
| Medical Equipment Industry Average Movement | 5.6% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 14.6% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: LT3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: LT3's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 622 | Michael Dale | www.axogeninc.com |
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue.
Axogen, Inc. Fundamentals Summary
| LT3 fundamental statistics | |
|---|---|
| Market cap | €1.31b |
| Earnings (TTM) | -€13.53m |
| Revenue (TTM) | €194.02m |
Is LT3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LT3 income statement (TTM) | |
|---|---|
| Revenue | US$225.21m |
| Cost of Revenue | US$57.86m |
| Gross Profit | US$167.35m |
| Other Expenses | US$183.06m |
| Earnings | -US$15.70m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 74.31% |
| Net Profit Margin | -6.97% |
| Debt/Equity Ratio | 40.6% |
How did LT3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/05 17:31 |
| End of Day Share Price | 2026/03/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Axogen, Inc. is covered by 18 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Caitlin Cronin | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |
| David Turkaly | Citizens JMP Securities, LLC |